The novelty of this study lies in the development, for the first time, of a causal pathway linking mitochondria-related genes, metabolic pathways, and cholelithiasis through multi-omics integration, providing theoretical support for personalized therapies targeting specific genes like LIAS and HEBP1. Here, LIAS is linked to cholelithiasis.